# Fresenius Medical Care account plan

> Fresenius Medical Care runs 3,601 dialysis centers and makes dialysis products for 140+ countries, with €19,628 M of 2025 revenue.

## At a glance

Fresenius Medical Care (FME), headquartered in Bad Homburg v. d. Höhe, Germany, is a vertically integrated kidney care group: it runs the world's largest dialysis clinic network (3,601 clinics in more than 30 countries treating 291,902 patients at end-2025) and makes dialysis machines, dialyzers and consumables sold in more than 140 countries. About 70% of its patients are treated in the U.S., where it treats about 37% of dialysis patients. In 2025 revenue was €19,628 M (+5% at constant currency), operating income excluding special items €2,212 M (11.3% margin) and net income attributable to shareholders €978 M. It employed 109,698 people at end-2025 and 107,226 at June 30, 2026.

## Business units

- **Care Delivery** (€13,736 M 2025 revenue (before eliminations)): The dialysis clinic network: in-center hemodialysis and hemodiafiltration, home dialysis, hospital services, vascular access, clinical research and dialysis pharmacy; revenue is 84% U.S. Operating income was €1,614 M in 2025 at an 11.8% margin. Led by Management Board member Craig Cordola.
- **Care Enablement** (€5,476 M 2025 revenue (before eliminations); around 35% of the dialysis products market): The MedTech business: hemodialysis machines such as the 5008X CAREsystem, PD cyclers, dialyzers, solutions, bloodlines, water treatment and critical care products, made in plants including St. Wendel, Schweinfurt, Ogden and Changshu. Operating margin was 6.0% in 2025, hit by volume-based procurement in China. Joseph E. Turk has led it since January 1, 2026.
- **Value-Based Care** (€2,247 M 2025 revenue (before eliminations)): Interwell Health, the U.S. risk-based kidney care business that manages the total cost of care of CKD and ESKD patients with payors, with membership of 162,697 in 2025. It reached break-even for the first time in 2025. Tommy O'Connor became CEO of Interwell Health in October 2025.

## Strategic priorities

- **FME Reignite strategy to 2030**: Strengthen core operations, drive profitable growth and innovation, and develop the culture; aspiration of a mid-teens operating income margin by 2030 and operating income CAGR of 3-7% from 2025 to 2028.
- **High-volume hemodiafiltration in the U.S.**: Replace about 20% of its own U.S. machines with the 5008X in 2026, training more than 7,200 nurses and technicians and moving around 36,000 patients across 28 states, with the goal of 100% by 2030.
- **FME25+ savings**: €804 M of sustainable savings by end-2025, €920 M by mid-2026, and a target of €1.2 BN by end-2027 across supply chain, procurement, clinic footprint and Global Business Services.
- **Restore U.S. referral capture**: U.S. same market treatment growth was -0.9% in Q2 2026; organizational changes in business development aim to improve referral conversion, with recovery seen mostly in 2027 and an aspiration to return to +2% plus.
- **Capital returns and leverage**: Dividend payout of 30-40%, a new ~€1 BN buyback launched in May 2026, capex of about €0.8-1.0 BN a year and a net leverage target of 2.5-3.0x.

## Latest results

In Q2 2026 revenue was €4,861 M (+4% at constant currency, 5% organic) and operating income excluding special items €569 M, up 23% at constant currency; Care Delivery operating income rose 33% at constant currency on TDAPA reimbursement, rate increases and FME25+ savings. For H1 2026 revenue was €9,473 M and net income attributable to shareholders €336 M (-11%). U.S. volumes fell, which management called "our own clear operational miss" in referral capture. The 2026 outlook was confirmed in October: revenue broadly flat and operating income within a +/- mid-single-digit range of €2,212 M, with negative H2 earnings growth as TDAPA turns into a headwind.

## Investments and deals

- **5008X fleet rollout**: By late July 2026, 227 clinics in 23 states were converted (10% of the machine base) and about 5,000 nurses and technicians trained; 2026 capex is expected at about €0.8-1.0 BN.
- **Share buybacks**: The first €1 BN program was completed in April 2026 with 24,848,819 shares; a new ~€1 BN program runs to May 27, 2027, with 9.1m shares bought for €357.1m by September 30, 2026.
- **Legacy portfolio optimization**: Exits from clinic operations in Brazil, Malaysia and Kazakhstan, sale of select Spectra Laboratories assets, and in China discontinuation of the 4008A platform with about €110 M of one-time costs.
- **ERP and production sites**: Move to SAP S/4HANA (around €80 M of 2026 corporate costs) and purchase of the Schweinfurt and St. Wendel production sites for €181 M in 2025.

## Challenges and risks

- **U.S. volume capture**: U.S. same market treatment growth is expected around -0.9% for 2026 after an organizational redesign and around 100 clinic exits in H1 disrupted referrals.
- **Reimbursement headwinds**: TDAPA phosphate binder add-ons end in 2027, ACA subsidy expiry costs €50 M in 2026, and the proposed 2027 ESRD bundle rises only 1.1%.
- **China volume-based procurement**: Volume-based procurement and stricter tenders in China weigh on Care Enablement, with an impact around €50 M for 2026.
- **Quality, cyber and supply costs**: FDA warning letters led to a quality management enhancement program; a cybersecurity incident occurred in late September 2026; the Middle East conflict raised procurement risk to medium.
- **Leadership change**: Shervin J. Korangy succeeded Helen Giza as CEO on October 12, 2026, as the Supervisory Board judged the transformation "has largely achieved its objectives".

## What leadership says

> "We are not seeing a market issue. We are seeing a volume capture issue in terms of getting the patients that we see into our clinics." — Helen Giza, then CEO, Q2 2026 earnings call, August 4, 2026

> "2025 was a milestone year for Fresenius's Medical Care. We delivered an outstanding step up in profitability" — Helen Giza, then CEO, Q4 and full year 2025 earnings call, February 24, 2026

> "We knew 2026 will be a transition year, which does not change our aspiration to achieve industry-leading growth and margins." — Helen Giza, then CEO, Q4 and full year 2025 earnings call, February 24, 2026


## Where a supplier can help

- **Clinical training and change management for HDF**: Converting thousands of machines and training thousands of clinicians in the 5008X rollout creates demand for training, field service and logistics support tied to the HDF priority.
- **Referral management and patient intake**: The U.S. volume shortfall is a referral conversion issue; referral tracking, CRM, insurance verification and patient onboarding tools address it directly.
- **Procurement and supply chain savings**: FME25+ targets supply chain, procurement and Global Business Services savings, and Middle East inflation raised procurement risk; sourcing, logistics and spend analytics offers fit.
- **Quality and cybersecurity**: FDA warning letters and a September 2026 cyber incident point to needs in quality management systems, regulatory compliance and security for connected devices.
- **ERP migration**: The SAP S/4HANA move carries tens of millions of euros of 2026 costs; integration, data migration and implementation partners fit this investment.

_Tamtam's reading of the priorities and challenges above, not the company's own words._

## Key documents

### [Annual Report 2025 ("The power of care")](https://freseniusmedicalcare.com/content/dam/fresenius-medical-care/global/en/04_media/pdf/publications/2025/FME_Annual_Report_2025_EN.pdf)

Annual report · 2026-03-12

- Fresenius Medical Care (FME) is the world's leading provider of products and services for people with kidney disease: a vertically integrated MedTech and healthcare services group headquartered in Bad Homburg v. d. Höhe, operating 3,601 dialysis centers in more than 30 countries for 291,902 patients and supplying products to customers in more than 140 countries.
- FY2025 revenue €19,628 M (+2% reported, +5% at constant currency); operating income €1,827 M reported and €2,212 M excluding special items; margin excluding special items 11.3% (9.3% reported). Net income attributable to shareholders €978 M (2024: €538 M); 109,698 employees.
- Three segments since June 2025: Care Delivery (€13,736 M revenue, dialysis clinics, 84% U.S.), Value-Based Care (€2,247 M, Interwell Health risk-based kidney care, first break-even year) and Care Enablement (€5,476 M, dialysis machines, dialyzers and consumables, ~35% share of the global dialysis products market).
- Strategy "FME Reignite" (launched at the June 2025 Capital Markets Day): aspiration of a mid-teens operating income margin by 2030 for the group, Care Delivery and Care Enablement; operating income CAGR of 3-7% from 2025 to 2028.
- FME25+ efficiency program: €804 M of sustainable savings by end-2025 (initial 2023 target €500 M); expanded target €1.2 BN by end-2027.
- Flagship innovation: U.S. rollout of the HDF-capable 5008X CAREsystem in 2026 (about 20% of its own U.S. machines, ~36,000 patients, >7,200 nurses and technicians trained), with the goal of replacing 100% by 2030; capex of around €0.8-1.0 BN a year.
- Capital returns: €1 BN share buyback (first tranche of €586 M completed December 2025), proposed dividend €1.49 (+3%), payout policy 30-40%, net leverage 2.5x (target 2.5-3.0x).
- 2026 outlook: revenue broadly flat at constant currency (Value-Based Care around €300 M lower from changed contracting), operating income at a consistent level within a +/- mid-single-digit range, implied margin 10.5-12.0%.
- Key risks: U.S. reimbursement (about 16% of revenue from U.S. federal programs; 63% of healthcare services revenue from U.S. private insurers), the end of TDAPA add-on payments for phosphate binders, ACA subsidy expiry and OBBBA Medicaid cuts, China volume-based procurement, labor costs and tariffs.

### [Interim Report Q2 2026 (half-year 2026)](https://freseniusmedicalcare.com/content/dam/fresenius-medical-care/global/en/03_investors/pdf/03_publications/2026/q2/Deutsche%20B%C3%B6rse%20Q2%202026_Englisch%20final.pdf)

Interim report · 2026-08-04

- Q2 2026 revenue €4,861 M (+1% reported, +4% at constant currency, 5% organic); operating income €466 M reported and €569 M excluding special items, +23% at constant currency; reported margin 9.6%.
- H1 2026 revenue €9,473 M (-2% reported, +3% at constant currency); operating income €752 M reported, €1,036 M excluding special items (+17% at constant currency); net income attributable to shareholders €336 M (-11%).
- Care Delivery drove profit: Q2 operating income €435 M (+33% at constant currency, margin 12.5%) on TDAPA reimbursement, rate increases and FME25+ savings, but U.S. same market treatment growth fell to -0.9% in Q2 (-0.6% in H1) after a significant organizational redesign and clinic footprint optimization disrupted referrals.
- Value-Based Care stayed profitable (Q2 operating income €17 M, margin 3.2%); Care Enablement grew on 5008X sales to FME's U.S. clinics but was hit by volume-based procurement and stricter tenders in China.
- Special items: a €71 M hit from the recommended revocation of the TAVNEOS marketing authorization (impairment at VFMCRP) and €208 M of FME25+ costs in H1.
- FME25+ cumulative sustainable savings reached €920 M; the first €1 BN buyback was completed (24,848,819 shares, 8.5% of share capital) and a new ~€1 BN program was launched in May 2026.
- 2026 outlook confirmed (revenue broadly flat, operating income at a consistent level +/- mid-single digit); Value-Based Care revenue now to fall €150-200 M instead of €300 M; U.S. same market treatment growth expected around the Q2 level for the year.
- Procurement risk raised to medium because of the Middle East conflict (oil, raw material and transport prices).

### [Q2 2026 earnings call transcript](https://freseniusmedicalcare.com/content/dam/fresenius-medical-care/global/en/03_investors/pdf/03_publications/2026/q2/Q2_2026_Earnings-call-transcript_Nasdaq.pdf)

Executive talk · Helen Giza, Chief Executive Officer and Chair of the Management Board (with Martin Fischer, Chief Financial Officer) · 2026-08-04

- Q2 2026 earnings call (August 4, 2026) with CEO Helen Giza and CFO Martin Fischer: operating income growth accelerated to 23%, with EUR67 million of FME25+ savings in the quarter.
- Giza called the U.S. volume decline "our own clear operational miss" in business development: referrals were not being converted into patients in FME clinics; U.S. same-market treatment growth was -0.9% and is now expected around that level for 2026.
- She insisted "We are not seeing a market issue" and put the recovery of referral rates mostly into 2027, after organizational changes in business development.
- 5008X rollout: 227 clinics in 23 states converted by late July (10% of the machine base), more than 600,000 treatments, about 5,000 nurses and technicians trained; BEACON-US real-world evidence study launched.
- Care Delivery operating income +45% with a 390 basis point margin step-up; TDAPA gave about EUR80 million year-on-year in Q2 but turns into a headwind in H2.
- Full-year TDAPA headwind cut to around EUR50 million (from EUR100 million); ACA subsidy expiry sized at EUR50 million; China headwind below EUR50 million for the year.
- Value-Based Care operating income EUR18 million; Care Enablement earnings down 5% on China and Middle East-driven raw material and logistics costs.
- New EUR1 billion buyback launched after the first one was completed; net leverage 2.6 times; outlook confirmed, with negative earnings growth expected in H2.

### [Q4 and full year 2025 earnings call transcript](https://freseniusmedicalcare.com/content/dam/fresenius-medical-care/global/en/03_investors/pdf/03_publications/2025/q4-fy/FME_Q4%202025_Transcript.pdf)

Executive talk · Helen Giza, Chief Executive Officer and Chair of the Management Board (with Martin Fischer, Chief Financial Officer) · 2026-02-24

- FY2025 earnings call (February 24, 2026) with CEO Helen Giza and CFO Martin Fischer, closing the FME25 mid-term plan: operating income growth of 27% reached the top end of the outlook and the group margin was 11.3%.
- Q4 2025 was exceptional: organic revenue growth 8%, earnings growth 53%, margin 13.9% (+430 basis points), Care Delivery margin 16.4%.
- Since the 2023 targets: Care Delivery margin raised to 13.1%, Care Enablement margin from nearly 2% to just over 8%, net leverage from 3.4 to 2.5 times; international clinic footprint cut to 25 core markets in 34 countries from 49.
- TDAPA was a big tailwind: about EUR220 million from phosphate binders and EUR90 million from a catheter lock solution in 2025, which offset around EUR80 million of unexpected medical benefit costs.
- 2026 called "a transition year": revenue broadly flat, operating income at a consistent level (+/- mid-single digit), margin 10.5% to 12%; regulatory headwinds of EUR150 million to EUR200 million.
- FME25+ extended to EUR1.2 billion of savings by end-2027; around 100 U.S. clinics to be closed in 2026.
- 5008X rollout: around 20% of FME's own installed base in 2026, about 36,000 patients across 28 states, benefits mainly in 2027 and beyond.
- New 2028 aspiration of 3% to 7% operating income CAGR (low teens excluding TDAPA noise); 2030 mid-teens group margin unchanged.

### [Pre-Q3 2026 Recent Key Messages (investor relations update)](https://freseniusmedicalcare.com/content/dam/fresenius-medical-care/global/en/03_investors/pdf/03_publications/2026/q3/FME_Q3_2026_Recent-Key-Messages.pdf)

Interim report · 2026-10-12

- Pre-Q3 2026 investor note (October 12, 2026) summarising FME's latest messages ahead of Q3 results on November 3, 2026.
- CEO change: Shervin J. Korangy, former CEO of BVI Medical and a Supervisory Board member since 2023, became CEO and Chairman of the Management Board on October 12, 2026, succeeding Helen Giza; the Supervisory Board said the transformation "has largely achieved its objectives".
- 2026 outlook unchanged: revenue broadly flat, operating income within a +/- mid-single-digit range of €2,212 M (implied margin 10.5-12.0%); H2 earnings growth negative as TDAPA turns into a headwind.
- U.S. same market treatment growth expected around -0.9% for 2026, with a further slight decline in Q3; return to +2% plus is still the aspiration, not time-stamped.
- TDAPA phosphate binders now contribute around €170 M in 2026 versus €220 M in 2025; DefenCath becomes a ~€90 M H2 headwind; ACA headwind €50 M.
- China: about €110 M one-time costs in Q3 for discontinuing the 4008A platform and PD portfolio actions; volume-based procurement seen as a "one-off pricing reset"; China impact around €50 M for the year.
- New issues: FDA warning letters with a quality management enhancement program, and a cybersecurity incident in late September with no impact on devices or patient care.
- Buyback: 9.1m shares bought for €357.1m by September 30 under the new €1 BN program; 259,509,365 shares outstanding.

## Questions about Fresenius Medical Care

### What does Fresenius Medical Care do?

It provides dialysis care through 3,601 clinics in more than 30 countries and makes dialysis machines, dialyzers and consumables, and runs a U.S. value-based kidney care business, Interwell Health.

### What was Fresenius Medical Care's revenue in 2025?

€19,628 M, up 5% at constant currency, with operating income excluding special items of €2,212 M.

### How many employees does Fresenius Medical Care have?

109,698 at end-2025 and 107,226 at June 30, 2026, with 54% in the U.S. at end-2025

### Who is the CEO of Fresenius Medical Care?

Shervin J. Korangy, former CEO of BVI Medical, became CEO and Chairman of the Management Board on October 12, 2026, succeeding Helen Giza; Martin Fischer is CFO.

### What is Fresenius Medical Care's strategy?

FME Reignite aims for a mid-teens operating margin by 2030, driven by the U.S. high-volume hemodiafiltration rollout, FME25+ savings of €1.2 BN by end-2027 and profitable growth.

_Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)_
